Galmed Pharmaceuticals Ltd
NASDAQ:GLMD

Watchlist Manager
Galmed Pharmaceuticals Ltd Logo
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Watchlist
Price: 0.88 USD -3.3% Market Closed
Market Cap: 4.8m USD

Galmed Pharmaceuticals Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Galmed Pharmaceuticals Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Galmed Pharmaceuticals Ltd
NASDAQ:GLMD
Pre-Tax Income
-$8.7m
CAGR 3-Years
27%
CAGR 5-Years
20%
CAGR 10-Years
1%
Kamada Ltd
NASDAQ:KMDA
Pre-Tax Income
$21.2m
CAGR 3-Years
N/A
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Urogen Pharma Ltd
NASDAQ:URGN
Pre-Tax Income
-$161.6m
CAGR 3-Years
-15%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Pre-Tax Income
-$10.8m
CAGR 3-Years
-28%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Pre-Tax Income
-$23.4m
CAGR 3-Years
14%
CAGR 5-Years
5%
CAGR 10-Years
1%
M
Matricelf Ltd
TASE:MTLF
Pre-Tax Income
-₪15.6m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Galmed Pharmaceuticals Ltd
Glance View

Market Cap
4.8m USD
Industry
Biotechnology

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Arachmol, the main product of Galmed Pharmaceuticals, is a liver-targeted stearoyl-coenzyme A desaturase1 used in oral therapy for the treatment of NASH (Non-alcoholic Steatohepatitis).

GLMD Intrinsic Value
3.77 USD
Undervaluation 77%
Intrinsic Value
Price

See Also

What is Galmed Pharmaceuticals Ltd's Pre-Tax Income?
Pre-Tax Income
-8.7m USD

Based on the financial report for Sep 30, 2025, Galmed Pharmaceuticals Ltd's Pre-Tax Income amounts to -8.7m USD.

What is Galmed Pharmaceuticals Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
1%

Over the last year, the Pre-Tax Income growth was -37%. The average annual Pre-Tax Income growth rates for Galmed Pharmaceuticals Ltd have been 27% over the past three years , 20% over the past five years , and 1% over the past ten years .

Back to Top